Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print])
- PMID: 31759509
- DOI: 10.1016/j.ophtha.2019.08.017
Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print])
Comment in
-
Reply.Ophthalmology. 2019 Dec;126(12):e96-e97. doi: 10.1016/j.ophtha.2019.08.016. Ophthalmology. 2019. PMID: 31759510 No abstract available.
Comment on
-
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12. Ophthalmology. 2020. PMID: 30986442 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
